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Abstract
Introduction The objective of this study was to determine and
compare the effectiveness of different prophylactic antifungal
therapies in critically ill patients on the incidence of yeast
colonisation, infection, candidemia, and hospital mortality.
Methods A systematic review was conducted of prospective
trials including adult non-neutropenic patients, comparing
single-drug antifungal prophylaxis (SAP) or selective
decontamination of the digestive tract (SDD) with controls and
with each other.
Results Thirty-three studies were included (11 SAP and 22
SDD; 5,529 patients). Compared with control groups, both SAP
and SDD reduced the incidence of yeast colonisation (SAP:
odds ratio [OR] 0.38, 95% confidence interval [CI] 0.20 to
0.70; SDD: OR 0.12, 95% CI 0.05 to 0.29) and infection (SAP:
OR 0.54, 95% CI 0.39 to 0.75; SDD: OR 0.29, 95% CI 0.18 to
0.45). Treatment effects were significantly larger in SDD trials
than in SAP trials. The incidence of candidemia was reduced by
SAP (OR 0.32, 95% CI 0.12 to 0.82) but not by SDD (OR 0.59,
95% CI 0.25 to 1.40). In-hospital mortality was reduced
predominantly by SDD (OR 0.73, 95% CI 0.59 to 0.93,
numbers needed to treat 15; SAP: OR 0.80, 95% CI 0.64 to
1.00). Effectiveness of prophylaxis reduced with an increased
proportion of included surgical patients.
Conclusion Antifungal prophylaxis (SAP or SDD) is effective in
reducing yeast colonisation and infections across a range of
critically ill patients. Indirect comparisons suggest that SDD is
more effective in reducing yeast-related outcomes, except for
candidemia.
Introduction
Yeast colonisation is quite common in intensive care unit (ICU)
populations. Up to 73% of patients have been reported to be
colonised by yeast, predominantly by Candida albicans [1].
Candida  species are among the most commonly isolated
microorganisms from the abdomen and urine in surgical
patients with infections [2].
The development of fungal/yeast infections is a rapidly
increasing health problem, especially in hospitalized patients
and in patients with impaired host defences. In 1995, yeast
was reported to be the fourth most common ICU-acquired
infection in Europe, where it represented approximately 17%
of all isolates [3]. This percentage may be even higher now,
although more recent data are lacking. Particularly in patients
with peritonitis, Candida frequently can be cultured from the
abdomen, with prevalences as high as 30% to 40% [4-7].
Systemic yeast infections are associated with high mortality,
often more than 50% [8], with C. albicans as the predominant
species responsible [9]. Systemic fungal/yeast infections have
become more common over the past two decades. Candida
is the fourth leading cause of all nosocomial bloodstream
infections in the US, accounting for up to 11% of all infections
[10]. As early as the 1980s, an increase in surgical yeast infec-
ALI = acute lung injury; APACHE II = Acute Physiology and Chronic Health Evaluation II; ARDS = acute respiratory distress syndrome; CI = confi-
dence interval; DF = degree of freedom; IQR = interquartile range; NNT = number needed to treat; OR = odds ratio; RCT = randomised controlled 
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tions from 2.5/1,000 discharges to 5.6/1,000 discharges was
observed [11]. The incidence of candidemia increased to 9.8/
1,000 ICU admissions among postoperative ICU patients in
1999 [12]. In another study, the incidence increased from
1.25/10,000 in 1999 to 3.06/10,000 patient-days per year in
2003 [13]. Invasive yeast infections are associated with high
morbidity and mortality, and the cost of bloodstream Candida
infection alone is already approaching $1 billion per year in the
US [14].
Proper management of yeast infections is challenging
because the diagnosis is often elusive. At present, laboratory
tests can be inconclusive (blood cultures have a sensitivity of
only 70% [15]) and it is difficult to distinguish between colo-
nisers and pathogens. Yeast is part of the physiological micro-
biological flora, thus positive cultures may merely reflect
colonisation or environmental contamination instead of actual
infection. On the other hand, the gold standard for the diagno-
sis of candidemia, blood culture, is not perfect. False-negative
blood cultures, especially, are a problem because sensitivity is
approximately 70% [15].
Given the high and increasing incidence of Candida infection,
its major clinical impact, and the lack of tests for an early and
accurate diagnosis, a prophylactic approach for high-risk
patients might be beneficial. Previous reviews on this topic
have analysed specific yeast prophylaxis regimens with either
a single-drug antifungal prophylaxis (SAP) or a multi-drug reg-
imen of selective decontamination of the digestive tract (SDD).
There are no direct randomised comparisons between SAP
and SDD treatments. Our aim is to review and compare the
effectiveness of both therapeutic strategies on yeast colonisa-
tion, invasive yeast infection, candidemia, and in-hospital
mortality.
Materials and methods
Search strategy
To identify eligible studies, a computer-assisted search was
performed in the following medical databases: Medline (Janu-
ary 1966 to January 2006), Cochrane Database of Systematic
Reviews, Cochrane Clinical Trials Register, Database of
Abstracts on Reviews and Effectiveness, and EMBASE (Janu-
ary 1950 to January 2006). Search terms included 'Candida',
'yeast', 'fungal', 'antimycotic', 'antifungal', 'prophylaxis', 'pre-
emptive', 'SDD', and 'SGD' (selective gut decontamination).
Clinical studies published in English, German, or French were
included. A manual cross-reference search of the eligible
papers was performed to identify additional relevant articles.
No unpublished data or data from abstracts were included in
the review.
Inclusion and exclusion criteria definitions
Clinical studies were eligible for inclusion if they assessed
adult non-neutropenic patients without concurrent immune
suppression (due to chemotherapy, solid organ or bone mar-
row transplantation, neutropenia, or HIV/AIDS) undergoing
preventive (pre-emptive or prophylactic) antimycotic therapy
with any antifungal agent. Prophylaxis in this review is defined
as antifungal therapy without a proven fungal infection. Pre-
emptive therapy is defined as antifungal therapy given for a
non-proven, but suspected, fungal infection.
Studies were excluded if they were retrospective or if they did
not compare the treated patient group with a control group
that either received no antifungal therapy or received placebo.
Studies examining the effects of antifungal prophylaxis without
measuring or reporting the incidence of Candida  or yeast
infection or colonisation were also excluded.
We aimed to retrieve the following outcomes from all studies:
(a) yeast colonisation defined as positive yeast culture
obtained from sputum, stool, urine, and/or wound without clin-
ical signs of infection/inflammation, (b) invasive yeast infection
defined as positive yeast culture obtained from presumed ster-
ile sites (peritoneal cavity, deep tissue, invasive burn wound, or
bronchoalveolar lavage fluid) with clinical signs of infection/
inflammation, (c) candidemia defined as positive yeast culture
from two or more blood cultures, (d) all-cause in-hospital mor-
tality, and (e) mortality directly attributable to yeast infection.
The definitions of colonisation and infection varied between
individual studies, but results were extracted using the above-
mentioned definitions.
The methodological quality of the individual studies was
scored using the Jadad scale, rated by one author (JvT). This
is a well-known instrument assigning a numerical score
between 0 and 5 to each study, reflecting its quality (0 indicat-
ing poor quality and 5 high quality) [16]. The research was car-
ried out in compliance with the World Medical Association
Declaration of Helsinki [17].
Statistical analysis
Patient characteristics of included patients are presented as
medians with 25% to 75% interquartile range (IQR). The
effectiveness of either therapy (SAP or SDD) compared to
their control group was expressed using odds ratios (ORs)
with 95% confidence intervals (CIs). An OR of less than 1 sig-
nifies a reduced risk of developing an adverse outcome in a
prophylaxis group compared to controls. Random effects
models were used to calculate pooled ORs and 95% CIs
across studies. To improve interpretability of results, we also
calculated the number needed to treat (NNT). NNT indicates
the number of patients who have to be treated with antifungal
prophylactic treatment in order to avoid one adverse outcome.
NNT was calculated by taking the reciprocal of the risk differ-
ence, which is the absolute arithmetic difference in rates of
outcomes between treated and control participants. Studies
were heterogeneous when more variation between the study
results was observed than would be expected to occur by
chance alone. Heterogeneity in results across studies wasAvailable online http://ccforum.com/content/11/6/R126
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assessed by the Q test with κ – 1 degrees of freedom (DFs)
and by calculating I2. I2 is a measure of inconsistency describ-
ing the percentage of total variation across studies that is due
to heterogeneity rather than chance.
Analysis strategy
Firstly, pooled ORs for SAP and SDD studies were calculated
separately. A formal test of interaction (meta-regression model
to test the null hypothesis that the difference in random effects
pooled ORs of SAP versus SDD studies is zero) was per-
formed to determine whether there was evidence that the
pooled OR was different between SAP and SDD studies. If
there was no indication for a treatment difference (p value of
interaction test above 0.1), a summary OR was calculated
combining SAP and SDD studies. In an additional analysis, it
was examined whether the proportion of surgical patients
could have influenced the observed differences in effective-
ness between SAP and SDD studies, because it has been
suggested that surgical patients are specifically at risk of
developing a yeast infection [18] and would benefit most from
antifungal therapy [19]. The effect of the proportion of surgical
patients as a confounder on outcomes was assessed by com-
paring crude relative OR (crude OR SAP divided by crude OR
SDD) and relative OR adjusted for the proportion of surgical
patients (adjusted OR SAP divided by adjusted OR SDD). The
proportion of surgical patients included was regarded as a
confounder when a difference of 10% or more between crude
and adjusted relative ORs was found. Within the group of SAP
studies, it was also examined whether systemic (absorbable)
drugs were more or less effective than non-absorbable enteral
antifungal drugs, comparing the crude and adjusted ORs
using logistic regression.
Because of the risk of publication bias, a 'failsafe N' was cal-
culated for the meta-analyses with significantly positive out-
comes. This number denotes the number of studies with null
results that would need to be added to the meta-analysis in
order for an effect to no longer be reliable, the so-called 'file
drawer studies' [20,21]. The magnitude of this sample is a
measure for the validity of the conclusions of the analyses in
this review.
Data analysis was performed using Review Manager 4.2.8
software (The Cochrane Collaboration, Oxford, Oxfordshire,
UK), SAS (Statistical Analysis System) software version 9.1
(SAS Institute Inc., Cary, NC, USA), and Statistical Package
for the Social Sciences version 11.5 (SPSS Inc., Chicago, IL,
USA). All p values were two-sided, with p values less than
0.05 indicating statistical significance.
Results
Studies
In all, 57 clinical studies examined either the SAP or SDD reg-
imen in adult patients (Figure 1). No studies directly compar-
ing SAP versus SDD were found. Twenty-four of these studies
were excluded. Table 1 presents the reasons for exclusion: the
studies did not report on Candida/yeast/fungus infection/col-
onisation or fungemia/candidemia (n = 14), they reported per-
centages of positive Candida cultures among cultures instead
of among patients (n = 4), they had a retrospective design (n
= 4), or they had no control group (n = 2). Therefore, a total of
33 prospective studies were included in this review: 11 stud-
ies examining the effects of SAP and 22 studies on SDD.
Study and patient characteristics are presented in Tables 2
and 3 for SAP and in Tables 4 and 5 for SDD. Table 6 presents
a summary of outcome parameters reported in the 33 included
studies.
In the analysis of SAP studies, 10 randomised controlled trials
(RCTs) and 1 prospective intervention study with a historical
control group were included (Table 2). In the analysis of SDD
studies, 19 RCTs, 2 prospective cohort studies, and 1 non-
randomised placebo-controlled study were included (Table 4).
The median quality score of the RCTs was good: 3.5 (IQR 3
to 5) for the SAP studies and 3 (IQR 2 to 4) for the SDD stud-
ies. Of the 29 RCTs, 20 described the method of randomisa-
tion and 15 were double-blinded. In 1 study, the randomisation
method was inappropriate [22].
A total of 5,529 patients were analysed: 2,947 patients
received antifungal prophylaxis (1,199 in SAP studies and
1,748 in SDD studies) and 2,582 controls received no
prophylaxis (1,032 in SAP studies and 1,550 in SDD studies).
The general characteristics did not differ between treated
patients and control patients. The median age was 55 (IQR 48
to 59) years, median proportion of females 38% (IQR 31% to
Figure 1
Flowchart showing study inclusion and exclusion Flowchart showing study inclusion and exclusion. SAP, single-drug 
antifungal prophylaxis; SDD, selective decontamination of the digestive 
tract.Critical Care    Vol 11 No 6    van Till et al.
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43%), median APACHE II (Acute Physiology and Chronic
Health Evaluation II) score 16 (IQR 13 to 19), and median pro-
portion of surgical patients 49% (IQR 24% to 77%).
Risk factors known to be independently associated with Can-
dida  infection and candidemia in multivariate analysis
(APACHE II, corticosteroid use, colonisation intensity, renal
failure/hemodialysis, total parenteral nutrition, and central
venous catheter [18,23]) were surveyed. When reported,
there were no significant differences between treated patents
and controls or between SAP and SDD groups. However, very
few studies actually reported these factors, and no firm con-
clusions can be drawn. The same was encountered when the
contribution of concurrent antibiotic or corticosteroid therapy
was examined.
Comparison of pooled characteristics between SAP and SDD
groups showed no significant differences, except for the pro-
portion of surgical patients, which was a median of 73% (IQR
43% to 100%) in the SAP group versus 43% (IQR 17% to
62%) in the SDD group (p = 0.016). The proportion of surgi-
cal patients approximated the percentage of patients who
underwent a laparotomy at the least. However, several studies
presented only the proportion of surgical patients, without
specifying the procedure. It was not possible to compare gas-
trointestinal surgery with other surgery.
Colonisation
Fifteen studies (5 out of 11 SAP studies and 10 out of 22 SDD
studies) published data on yeast colonisation (Table 6).
Pooled data showed a highly significant reduction of the risk
Table 1
Excluded studies examining antifungal prophylaxis in adult non-neutropenic patients (n = 24)
Reference Year Endpoint Exclusion Design
Stoutenbeek et al. [41] 1984 SDD in ICU patients Only yeast as percentage of cultures Cohort
Slotman et al. [42] 1988 Ketoconazole prophylaxis in ALI/ARDS No yeast scored RCT
Flaherty et al. [43] 1990 SDD in ICU patients No yeast scored RCT
Godard et al. [44] 1990 SDD in ICU patients No yeast scored (+ no control group) RCT
Rodriguez-Roldán et al. [45] 1990 SDD in ICU patients No yeast scored RCT
Tetteroo et al. [46] 1990 SDD in oesophageal resection No yeast scored RCT
Gastinne et al. [47] 1992 SDD in ICU patients No yeast scored RCT
Jacobs et al. [48] 1992 SDD in ICU patients No yeast scored RCT
Rocha et al. [49] 1992 SDD in ICU patients No yeast scored RCT
Korinek et al. [50] 1993 SDD in neurosurgical ICU patients Only yeast as percentage of cultures RCT
Yu and Tomasa [51] 1993 Ketokonazole prophylaxis in ARDS No yeast scored RCT
Misset et al. [52] 1994 SDD in ICU patients No control group RCT
Sorkine et al. [53] 1996 Amphotericin B treatment in Candida sepsis No control group RCT
Lingnau et al. [54] 1997 SDD in multiple trauma patients No yeast scored RCT
Palomar et al. [55] 1997 SDD in ICU patients No yeast scored RCT
Safran and Dawson [56] 1997 Fluconazole prophylaxis in SICU patients Retrospective (+ no control group) Cohort
Schardey et al. [57] 1997 SDD in total gastrectomy Only yeast as percentage of cultures RCT
Sánchez García et al. [58] 1998 SDD in ICU patients Only yeast as percentage of cultures RCT
ARDS network [59] 2000 Ketoconazole prophylaxis in ALI/ARDS No yeast scored RCT
Pneumatikos et al. [60] 2002 Subglottal decontamination No yeast scored RCT
De Waele et al. [61] 2003 Fluconazole prophylaxis in pancreatitis Retrospective Cohort
Swoboda et al. [62] 2003 Fluconazole prophylaxis in SICU patients Retrospective Cohort
Magill et al. [63] 2004 Fluconazole prophylaxis in SICU patients No yeast scored RCT
Shan et al. [64] 2006 Early presumptive therapy in GI surgery Retrospective Cohort
Reasons for exclusion: no yeast outcomes reported (n = 14), only yeast as percentage of cultures (n = 4), no control group (n = 2), retrospective 
design (n = 4). ALI, acute lung injury; ARDS, acute respiratory distress syndrome; GI, gastrointestinal; ICU, intensive care unit; RCT, randomised 
controlled trial; SDD, selective decontamination of the digestive tract; SICU, surgical intensive care unit.Available online http://ccforum.com/content/11/6/R126
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Table 2
General characteristics of individual studies on prophylactic antifungal therapy using a single-drug antifungal prophylaxis regimen
Reference Year Country Inclusion period Study design
Slotman and Burchard [65] 1987 USA October 1982 to July 1985 RCT
Savino et al. [25] 1994 USA July 1990 to December 1991 RCT
Eggimann et al. [4] 1999 Switzerland Not specified RCT
Ables et al. [66] 2000 USA October 1994 to December 1996 RCT
Pelz et al. [67] 2001 USA January 1998 to January 1999 RCT
Sandven et al. [6] 2002 Norway March 1994 to June 1995 RCT
Garbino et al. [68] 2002 Switzerland 30 months RCT
He et al. [69] 2003 China January 1998 to December 2002 RCT
Jacobs et al. [70] 2003 Saudi Arabia December 1998 to June 2001 RCT
Piarroux et al. [38] 2004 France August 1998 to July 2000 Intervention study
Normand et al. [24] 2005 France February 2002 to July 2002 RCT
RCT, randomised controlled trial.
Table 3
Clinical and design characteristics of individual studies on single-drug antifungal prophylaxis
Reference Inclusion Patients Group
Intervention (n)C o n t r o l  ( n)
Slotman and 
Burchard [65]
SICU, ≥3 risk factors for candidemia Surgical Ketoconazole, 200 mg, 1 dd oral (27) Placebo (30)
Savino et al. [25] Remaining or expected SICU stay of 
>48 hours
Surgical/Trauma A. Clotrimazole, 10 mg, 3 dd oral 
(80)
No prophylaxis (72)
B. Ketoconazole, 200 mg, 1 dd oral 
(65)
C. Nystatin, 2 × 106 U, 4 dd oral (75) 
(total 220)
Eggimann et al. [4] Recurrent GI perforation or 
anastomotic leakage
Surgical Fluconazole, 400 mg, 1 dd iv (23) Placebo (20)
Ables et al. [66] Expected SICU stay of >48 hours + 
risk factor for candidiasis
Surgical/Trauma Fluconazole, 400 mg, 1 dd oral/iv 
(60)
Placebo (59)
Pelz et al. [67] SICU stay of ≥3 days Surgical Fluconazole, 400 mg, 1 dd oral (130) Placebo (130)
Sandven et al. [6] Confirmed intra-abdominal perforation Surgical Fluconazole, 400 mg, 1× 
peroperative iv (53)
Placebo (56)
Garbino et al. [68] SICU stay of ≥3 days + mechanical 
ventilation for >48 hours
Surgical/Medical Fluconazole, 100 mg, 1 dd iv (103) Placebo (101)
He et al. [69] Severe pancreatitis Surgical Fluconazole, 100 mg, 1 dd iv (22) No prophylaxis (23)
Jacobs et al. [70] ICU patients + septic shock Surgical/Medical Fluconazole, 200 mg, 1 dd iv (32) Placebo (39)
Piarroux et al. [38]a Colonisation index of ≥0.4, SICU stay 
of ≥5 days
Surgical/Trauma Fluconazole, 400 mg, 1 dd iv (478) No prophylaxis (455)
Normand et al. [24] Mechanical ventilation for >48 hours Surgical/Medical Nystatin, 106 U, 3 dd oral (51) No prophylaxis (47)
aTreatment design is pre-emptive. dd, daily dose; GI, gastrointestinal; ICU, intensive care unit; iv, intravenous; RCT, randomised controlled trial; 
SICU, surgical intensive care unit.Critical Care    Vol 11 No 6    van Till et al.
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of colonisation for both prophylactic therapies (SAP studies:
pooled OR 0.38, 95% CI 0.20 to 0.70, NNT 5; SDD studies:
pooled OR 0.12, 95% CI 0.05 to 0.29, NNT 3) (Figure 2).
Non-significant heterogeneity was seen for the SAP studies
(DF = 4, p = 0.10, I2 = 48.7%), whereas heterogeneity was
indeed found for the SDD studies (DF = 9, p < 0.001, I2 =
73.5%). Both SAP and SDD reduced colonisation: from 37%
to 18% in SAP and from 45% to 10% in SDD. The difference
between the ORs of SAP and SDD was significant (test for
interaction p = 0.020), with the effect in SDD studies being
3.6 times higher than in SAP studies (relative OR 3.62, 95%
CI 1.12 to 11.77). The failsafe N values for SAP and SDD
were 25 and 194, respectively.
Invasive infection
Data on invasive yeast infection were available from 25 studies
(10 SAP studies and 15 SDD studies) (Table 6). A significant
reduction of the risk of invasive infection was found (Figure 3)
for SAP studies with a pooled OR of 0.54 (95% CI 0.39 to
0.75, NNT 20) and for SDD studies with a pooled OR of 0.29
(95% CI 0.18 to 0.45, NNT 18). Heterogeneity of included
studies was not significant for either set of studies (SAP: DF
= 8, p = 0.40, I2 = 3.8%; SDD: DF = 14, p = 0.45, I2 = 0%).
The effect on yeast infection was significantly more pro-
nounced in SDD studies than in SAP studies (test for
interaction p = 0.036; relative OR 2.0, 95% CI 1.1 to 3.7).
SDD reduced the incidence of invasive infection from 8% in
control patients to 3% in prophylaxis patients. The failsafe N
values for SAP and SDD were 26 and 101, respectively.
It was not possible to determine the ability of the preventative
therapies to prevent pure invasive yeast infection unencum-
bered by concomitant bacterial infection (polymicrobial
infections), as most studies did not provide data on concurrent
microbial cultures. Too few studies reported data on colonisa-
Table 4
General characteristics of individual studies on prophylactic antifungal therapy as a part of a selective decontamination of the 
digestive tract regimen
Reference Year Country Inclusion period Study design
Unertl et al. [71] 1987 Germany May 1984 to January 1985 RCT
Ledingham et al. [72] 1988 UK July 1985 to November 1986 Cohort
Kerver et al. [73] 1988 The Netherlands January 1985 to May 1986 RCT
Von Hünefeld [22] 1989 Germany 1987 to 1989 RCT
Ulrich et al. [74] 1989 The Netherlands October 1986 to September 1987 RCT
McClelland et al. [75] 1990 UK January 1987 to December 1987 Cohort
Hartenauer et al. [76] 1990 Germany 1989 to 1990 Non-random CT
Gaussorgues et al. [77] 1991 France September 1988 to September 1991 RCT
Blair et al. [78] 1991 UK September 1988 to January 1990 RCT
Aerdts et al. [79] 1991 The Netherlands May 1985 to September 1987 RCT
Cerra et al. [80] 1992 USA Not specified RCT
Hammond et al. [81] 1992 South Africa January 1989 to December 1990 RCT
Saunders et al. [82] 1994
Cockerill et al. [83] 1992 USA 1986 to 1989 RCT
Winter et al. [84] 1992 UK 22 months RCT
Ferrer et al. [85] 1994 Spain Not specified RCT
Langlois-Karaga et al. [86] 1995 France 2 years RCT
Luiten et al. [87] 1995 The Netherlands April 1990 to April 1993 RCT
Wiener et al. [88] 1995 USA 8 months RCT
Quinio et al. [89] 1996 France Not specified RCT
Verwaest et al. [90] 1997 Belgium 19 months RCT
Abele-Horn et al. [91] 1997 Germany Not specified RCT
de La Cal et al. [92] 2005 Spain May 1997 to January 2000 RCT
CT, controlled trial; RCT, randomised controlled trial.Available online http://ccforum.com/content/11/6/R126
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tion and infection of specific infected body sites to draw a
conclusion on which body sites principally benefited from anti-
fungal prophylaxis.
Candidemia
Data on candidemia were published in 18 studies (6 SAP
studies and 12 SDD studies) (Table 6). The analysis of SAP
studies showed a significant reduction of the risk of candi-
demia by prophylactic therapy (pooled OR 0.32, 95% CI 0.12
to 0.82, NNT 38) (Figure 4), reducing the incidence of candi-
demia from 3.8% in controls to 1.2% in treated patients. The
pooled OR for SDD studies was 0.59, with a wide CI that
included 1 (95% CI 0.25 to 1.40) (Figure 4). Heterogeneity of
included studies was not significant for SAP studies (DF = 4,
p = 0.25, I2 = 26.4%) or for SDD studies (DF = 9, p = 0.71, I2
= 0%). A formal test of interaction for a difference in treatment
effect (pooled ORs) between SAP and SDD studies was not
statistically significant (p = 0.34), and the overall pooled OR
Table 5
Clinical and design characteristics of individual studies on selective decontamination of the digestive tract
Reference Inclusion Patients Group
Interventions (n)C o n t r o l  ( n)
Unertl et al. [71] Expected mechanical ventilation of >6 days Surgical/Trauma/Medical Amphotericin B, 300 mg,
4 dd oral (19)
Placebo (20)
Ledingham et al. 
[72]
All ICU patients Surgical/Medical Amphotericin B, 500 mg,
4 dd oral (163)
No prophylaxis (161)
Kerver et al. [73] ICU stay of >5 days + mechanical 
ventilation
Surgical/Trauma Amphotericin B, 500 mg,
4 dd oral (49)
No prophylaxis (47)
Von Hünefeld [22] Mechanical ventilation for >4 days Surgical/Trauma Amphotericin B, 500 mg,
4 dd oral (102)
No prophylaxis (102)
Ulrich et al. [74] Expected ICU stay of >5 days Surgical/Trauma/Medical Amphotericin B, 500 mg,
4 dd oral (48)
Placebo (52)
McClelland et al. 
[75]
Acute respiratory and renal failure, 
mechanical ventilation and hemodialysis for 
>5 days
Surgical/Trauma/Medical Amphotericin B, 500 mg,
4 dd oral (15)
No prophylaxis (12)
Hartenauer et al. 
[76]
Mechanical ventilation for >3 days, ICU stay 
of >5 days
Surgical/Trauma Amphotericin B, 500 mg, 
4 dd oral (99)
No prophylaxis (101)
Gaussorgues et al. 
[77]
Mechanical ventilation + inotropic therapy Surgical/Medical Amphotericin B, 500 mg, 
4 dd oral (59)
Placebo (59)
Hammond et al. 
[81]
Expected mechanical ventilation of >48 
hours, expected ICU stay of >5 days
Surgical/Trauma/Medical Amphotericin B, 500 mg, 
4 dd oral (114)
Placebo (125)
Cockerill et al. [83] ICU stay of ≥3 days Surgical/Trauma/Medical Nystatin, 105 U, 4 dd oral 
(75)
No prophylaxis (75)
Winter et al. [84] ICU stay of >2 days Surgical/Trauma/Medical Amphotericin B, 500 mg, 
4 dd oral (91)
No prophylaxis (92)
Ferrer et al. [85] Expected mechanical ventilation of >3 days Surgical/Trauma/Medical Amphotericin B, 500 mg, 
4 dd oral (39)
Placebo (40)
Langlois-Karaga et 
al. [86]
ICU stay of >2 days Trauma Amphotericin B, 500 mg, 
4 dd oral (47)
Placebo (50)
Luiten et al. [87] Severe pancreatitis Surgical/Medical Amphotericin B, 500 mg, 
4 dd oral (50)
No prophylaxis (52)
Wiener et al. [88] Expected mechanical ventilation of >48 
hours
Surgical/Medical Nystatin, 105 U, 4 dd oral 
(30)
Placebo (31)
Quinio et al. [89] ICU patients + mechanical ventilation Trauma Amphotericin B, 500 mg, 
4 dd oral (76)
Placebo (72)
Verwaest et al. [90] Expected mechanical ventilation of >48 
hours
Surgical/Trauma Amphotericin B, 500 mg, 
4 dd oral (393)
No prophylaxis (185)
Abele-Horn et al. 
[91]
Mechanical ventilation for >48 hours Surgical/Medical Amphotericin B, 500 mg, 
4 dd oral (58)
No prophylaxis (30)
de La Cal et al. [92] ≥20% of body surface burned, inhalation 
trauma + ICU stay of ≥3 days
Trauma Amphotericin B, 500 mg, 
4 dd oral (53)
Placebo (54)
dd, daily dose; ICU, intensive care unit; RCT, randomised controlled trial.Critical Care    Vol 11 No 6    van Till et al.
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across all 18 studies was 0.39 (95% CI 0.21 to 0.72, NNT
59). The failsafe N for the SAP group was 25.
Mortality
Data on all-cause hospital mortality were published in 32 stud-
ies (all 11 SAP studies and 21 SDD studies) (Table 6). For
SAP studies, a pooled OR of 0.80 (95% CI 0.64 to 1.00) was
found, whereas the pooled OR for SDD studies was 0.73
(95% CI 0.59 to 0.93, NNT 15) (Figure 5). No heterogeneity
of included studies was found either for SAP studies (DF = 10,
p = 0.61, I2 = 0%) or for SDD studies (DF = 20, p = 0.10, I2
= 29.1%).
Table 6
Summary of outcomes presented in included studies
Reference Colonisation Infection Candidemia Mortality Attributable mortality
Abele-Horn et al. [91] x x
Ables et al. [66] x x
Aerdts et al. [79] x x x x
Blair et al. [78] x x x
Cerra et al. [80] x x x
Cockerill et al. [83] x x x
de La Cal et al. [92] x x
Eggimann et al. [4] x x x x
Ferrer et al. [85] x x x x
Garbino et al. [68] x x x x x
Gaussorgues et al. [77] x x
Hammond et al. [81], Saunders et al. [82] x x x
Hartenauer et al. [76] x x x
He et al. [69] x x
Jacobs et al. [70] x x x
Kerver et al. [73] x x
Langlois-Karaga et al. [86] x
Ledingham et al. [72] x x
Luiten et al. [87] x x
McClelland et al. [75] x x x
Normand et al. [24] x x x x
Pelz et al. [67] x x x
Piarroux et al. [38] x x x x
Quinio et al. [89] xx
Sandven et al. [6] x x
Savino et al. [25] x x x
Slotman and Burchard [65] x x x x
Ulrich et al. [74] x x x x
Unertl et al. [71] x x
Verwaest et al. [90] x x
Von Hünefeld [22] x x x x
Wiener et al. [88] x x x x
Winter et al. [84] x x xAvailable online http://ccforum.com/content/11/6/R126
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Figure 2
Yeast colonisation Yeast colonisation. Individual and pooled odds ratios (ORs) for yeast colonisation from studies comparing single-drug antifungal prophylaxis (SAP) 
versus control (upper part) and selective decontamination of the digestive tract (SDD) versus control (lower part) in adult non-neutropenic patients. 
The model used is a random effects meta-analysis. Test for overall effect: SAP: Z = 3.09 (p = 0.002); SDD: Z = 4.58 (p < 0.001). Difference in 
pooled ORs between SAP and SDD studies, test for interaction p = 0.020. CI, confidence interval.
Figure 3
Invasive yeast infection Invasive yeast infection. Random effects meta-analysis of the effect of single-drug antifungal prophylaxis (SAP) and selective decontamination of 
the digestive tract (SDD) on invasive yeast infection (per patient) in adult non-neutropenic patients. Test for overall effect: SAP: Z = 3.44 (p < 
0.001); SDD: Z = 5.28 (p < 0.001). Difference in pooled odds ratios (ORs) between SAP and SDD studies, test for interaction p = 0.036. CI, con-
fidence interval.Critical Care    Vol 11 No 6    van Till et al.
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The pooled ORs of SAP and SDD studies were not signifi-
cantly different (test for interaction p = 0.58). The pooled OR
across all 32 studies was 0.75 (95% CI 0.64 to 0.87, NNT
17). Prophylactic antifungal drug administration, being either
SAP or SDD, reduced mortality from 27% in controls to 21%
in treated patients. The failsafe N for the SDD group was 41.
Mortality directly attributable to yeast infection was studied in
6 studies (4 SAP and 2 SDD). Attributable mortality was sig-
nificantly reduced by prophylaxis: 0.5% in the prophylaxis
group versus 2.9% in the control group (pooled OR: 0.23,
95% CI 0.09 to 0.60, NNT 41).
The outcomes of studies with small sample size are more ham-
pered by play of chance than in large sized studies. When
studies of fewer than 50 patients or fewer than 100 patients
were excluded to exclude noise due to publication bias of
small-sample-size positive trials, ORs did not tend to change
significantly, except for the ORs of candidemia in the SDD
group, which were higher (0.69 [95% CI 0.26 to 1.87] and
0.81 [95% CI 0.26 to 2.46] for exclusion of studies fewer than
50 and fewer than 100 patients, respectively). This underlines
the already moderate non-significant effect of SDD on
candidemia.
Additional analyses
Surgical patients
Adjustment for the proportion of surgical patients in single
antifungal drug and SDD studies changed the difference in
pooled ORs between single-drug and SDD studies. Specifi-
cally, the proportion of surgical patients was a confounder to
the outcomes of colonisation and candidemia. The proportion
of surgical patients, on average, was higher in SAP studies
compared with SDD studies, as was shown by a reduction of
OR after adjustment in the SAP group (colonisation: SAP,
crude OR 0.41 [95% CI 0.24 to 0.68] to adjusted OR 0.30
[95% CI 0.11 to 0.86]; SDD, crude OR 0.12 [95% CI 0.05 to
0.29] to adjusted OR 0.12 [95% CI 0.04 to 0.36]; candi-
demia: SAP, crude OR 0.32 [95% CI 0.12 to 0.82] to
adjusted OR 0.16 [95% CI 0.06 to 0.44]; SDD, crude OR
0.59 [95% CI 0.25 to 1.40] to adjusted OR 0.78 [95% CI
0.27 to 2.22]).
After adjustment of the crude relative OR (OR SAP/OR SDD)
for the proportion of surgical patients, the adjusted relative OR
was significantly reduced for colonisation (crude relative OR
3.62, adjusted relative OR 2.53) as well as for candidemia
(crude relative OR 0.51, adjusted relative OR 0.21). Thus,
even after adjustment for confounding, the effect found in SDD
studies was still significantly different from that found in SAP
studies. For yeast infection and mortality, crude and adjusted
relative ORs were comparable.
Figure 4
Candidemia Candidemia. Random effects meta-analysis of the effect of single-drug antifungal prophylaxis (SAP) and selective decontamination of the digestive 
tract (SDD) on candidemia (per patient) in adult non-neutropenic patients. Test for overall effect: SAP: Z = 2.47 (p = 0.01); SDD: Z = 1.26 (p = 
0.21); both groups combined: Z = 3.04 (p = 0.002). Difference in pooled odds ratios (ORs) between SAP and SDD studies, test for interaction p = 
0.34. CI, confidence interval.Available online http://ccforum.com/content/11/6/R126
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Absorbable (systemic) versus non-absorbable (enteral) 
antifungal drugs
All SDD studies applied non-absorbable drugs, so no compar-
ison could be made within these studies. In three SAP studies,
patients received non-absorbable drugs: two studies applied
oral nystatin [24,25] and one study applied oral clotrimazole
[25]. Only one of these studies reported data on invasive
infection, thus no analysis could be performed concerning this
outcome.
ORs for systemic and enteral drugs were comparable for col-
onisation but differed for candidemia. Candidemia was signifi-
cantly reduced by systemic SAP (OR 0.22, 95% CI 0.09 to
0.52) but not by non-absorbable SAP (OR 1.36, 95% CI 0.37
to 5.03). This difference between ORs of candidemia between
groups was significant (test for interaction p = 0.022). For
mortality, the OR in studies with systemic drugs was 0.75
(95% CI 0.57 to 0.98) and in studies using non-absorbable
drugs was 0.97 (95% CI 0.58 to 1.61) (test for interaction p
= 0.37).
Discussion
Both methods of antifungal prophylaxis (SAP and SDD)
reduced the odds of developing Candida colonisation, inva-
sive infection, candidemia, and mortality to various degrees in
critically ill patients. The present comparative meta-analysis of
SAP and SDD antifungal prophylactic regimens allowed us to
analyse the differences between both antifungal strategies on
outcomes. This is important since no head-to-head compari-
son studies have been performed.
SDD was more effective in reducing yeast colonisation and
infection than single-drug prophylaxis. The clinical importance
of these effects on outcomes is illustrated by the fact that Can-
Figure 5
In-hospital mortality In-hospital mortality. Random effects meta-analysis of the effect of single-drug antifungal prophylaxis (SAP) and selective decontamination of the 
digestive tract (SDD) on all-cause in-hospital mortality (per patient) in adult non-neutropenic patients. Test for overall effect: SAP: Z = 1.97 (p = 
0.05); SDD: Z = 2.92 (p = 0.004); both groups combined: Z = 3.72 (p < 0.001). Difference in pooled odds ratios (ORs) between SAP and SDD 
studies, test for interaction p = 0.58. CI, confidence interval.Critical Care    Vol 11 No 6    van Till et al.
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dida colonisation or infection with an identical strain frequently
precedes advanced (bloodstream) infection in non-neutro-
penic patients [26,27]. Furthermore, the intensity of Candida
colonisation is an independent factor for the development of
Candida infection [23]. However, in a large prospective cohort
study, prior colonisation was not associated with bloodstream
infections [18]. The exact role of colonisation in yeast-related
disease should be elaborated further to fully appreciate the
effects of prophylactic therapy.
The risk of developing yeast infection was reduced 3.2-fold
(from 8.3% to 2.6%) by SDD, which was significantly more
effective than SAP. Since most SAP regimens comprise
absorbable (mostly intravenous) drugs and SDD contains
enteral non-absorbable drugs, these results corroborate the
hypothesis that the gastrointestinal tract is the primary source
of yeast causing infection. Alterations in the host defence of
critically ill patients (prior surgery, parenteral nutrition, hemodi-
alysis, and mechanical ventilation) imply immunosuppression
and/or a breach of the mucosal barrier [18,23,28]. This can
lead to overgrowth of Candida  species and increased
microbial translocation [7]. The difference in efficacy of SDD
compared to SAP could possibly be explained by the fact that
SDD reduces yeast load at the source of primary yeast coloni-
sation (that is, the gastrointestinal tract).
The incidence of candidemia was significantly reduced by
SAP, whereas the reduction in SDD studies was potentially
relevant but not statistically significant. Furthermore, the meta-
regression analysis revealed no significant difference between
the pooled ORs of both types of prophylaxis, so no definite
conclusions should be drawn. With a relatively high NNT of 38
for SAP and a relatively low incidence of candidemia of 3.8%
in these critically ill patients, the prophylactic use of SAP in the
general population of ICU patients does not seem justified, a
reported high mortality rate of 25% to 60% [29] in patients
with candidemia notwithstanding.
SDD led to a significant reduction in all-cause in-hospital mor-
tality. The decrease in mortality rate may be due, at least in
part, to the reduction of Candida infection by SDD, and anti-
fungal prophylaxis indeed decreased mortality directly
attributable to yeast. However, in the present review, SDD did
not significantly reduce the rate of candidemia, as was shown
in an earlier study [30]. A previous meta-analysis in critically ill
patients showed that pneumonia and Gram-negative as well
as overall bloodstream infections were reduced by SDD.
[19,31], which would account for the decrease in mortality.
The value of antifungal prophylaxis is likely to be much higher
in individuals who receive antibacterial agents, and the
reduced gastrointestinal microbial load may be a possible fac-
tor in the greater efficacy of SDD compared with SAP.
A systematic review of SDD in ICU patients found that mortal-
ity was reduced significantly in surgical patients only and not
in medical patients. [19]. In the present review, adjustment for
the proportion of surgical patients changed the difference in
effect between the two types of antifungal prophylaxis for the
outcomes of colonisation and candidemia. The difference in
effect of SAP compared to SDD became smaller, but the
direction of the difference was stable in favour of SDD. These
results show that the effectiveness of prophylaxis is reduced
with an increased proportion of included surgical patients.
The results of this review generally confirm the conclusions of
earlier reviews examining the separate effects on yeast infec-
tions of SDD [30,32] or SAP [33-35]. However, these reviews
have some shortcomings. The reviews on SDD/non-absorba-
ble antifungal prophylaxis included pediatric studies [30,32] or
liver transplant studies [30], which were excluded in the
present review. Previous reviews on systemic prophylaxis
included studies that included fluconazole studies only [33],
studies on surgical patients only [34], or studies that examined
groups with non-absorbable prophylaxis as control groups
[35]. The present review is the first to examine the two meth-
ods of antifungal prophylaxis concurrently, showing the pros
and cons of each regimen with respect to the outcomes of
yeast colonisation, infection, candidemia, and hospital
mortality.
The use of systemic (absorbable) drugs, like fluconazole, may
have to be restricted for two reasons. First, antifungal drug use
can initiate the possible emergence of azole-resistant strains.
The present study did not investigate this aspect. Playford and
colleagues [35] could find no significant increase of resistant
strains in a review of absorbable antifungal prophylaxis. How-
ever, the pooled estimates on the emergence of resistant
strains had wide CIs and could have suffered from insufficient
power. Thus, no definite conclusions can be drawn from these
observations. There is no compelling evidence to link prophy-
lactic antifungal therapy with resistance, but it is quite clear
that increased use of antifungal drugs has promoted the dis-
semination of azole-resistant fungi. This needs to be taken into
consideration when considering the risk-benefit ratio for insti-
tuting widespread use of antifungal prophylaxis in critical care
units. Second, systemic antifungal agents can have potential
toxic effects. [35]. Systemic drugs may be advised as prophy-
laxis only in patients with increased risk of developing Candida
bloodstream infections [18,23,28]. SDD may have fewer sys-
temic side effects and thus can be given to critically ill patients
to prevent Candida colonisation and infection. However, the
effect of SDD use on resistance patterns of yeast is still a mat-
ter of debate. SDD may decrease the emergence of antibiotic
resistance [36], but an increase in pathological bacteria (ente-
rococci and coagulase-negative staphylococci) is of concern
[37]. The matter of SDD-induced antifungal drug resistance is
unclear.
Several factors have to be considered while interpreting the
results of this review. First, most included studies had smallAvailable online http://ccforum.com/content/11/6/R126
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sample sizes and the event rates of several outcomes were
small. This means that individual studies had wide CIs, but
even CIs around pooled ORs were still wide, and therefore the
power for detecting clinically relevant differences for some
outcomes was small. It means also that subgroup analyses
have to be interpreted with care. Second, although the
methodological quality of the studies was good on average,
there is still room for improvement as only half of the studies
applied blinding of treatment allocation and outcome
assessment.
Third, studies used a wide variety of criteria for patient inclu-
sion and exclusion. In addition, definitions of yeast colonisation
and invasive yeast infection differed between studies as there
is still no consensus on this subject. The value of the effect of
prophylaxis on invasive yeast infection, especially, must be
interpreted with scepticism because definitions vary between
articles and it is debatable whether a mixed culture can be
seen as evidence of an invasive infection. Unfortunately, not all
articles published data on the culture results. The variation
among definitions hampers the comparison of these outcomes
between studies. In this review, we used widely accepted def-
initions and tried to redefine results if individual studies used
other definitions. In particular, the definitions of prophylactic
and pre-emptive treatment are often overlapping. Critically ill
patients in the ICU are often already colonised or may be
infected without being cultured, so prophylactic therapy can
often be seen as pre-emptive. However, pre-emptive therapy
will be given to a selected group of patients with a higher risk
of yeast infections. There was one study that compared a pre-
emptive strategy with a control group [38]. In the analysis of
our data, we made no distinction between prophylactic and
pre-emptive treatment strategies. Despite these differences in
populations and definitions, the results for most outcomes
were relatively homogeneous across studies with accompany-
ing values of the I2 statistic that were low.
Fourth, our review, like any other review, may have suffered
from publication or selective reporting bias. Studies with a
'negative' result may be less likely get published, and results
from non-significant outcomes are less likely to be reported
[39,40]. The number of these file drawer studies exceeded the
number of included studies in the analyses with positive
results, reducing the unreliability of the validity of the out-
comes. However, 14 studies provided antifungal therapy but
were excluded for not scoring yeast/fungi. These studies did
not state whether culture results were negative or whether no
specific cultures were performed. This may cause pooled
results of included trials, which are too optimistic.
Conclusion
Both SAP and SDD antifungal prophylaxis strategies were
effective in reducing yeast-associated disease across a range
of critically ill patients. The reduction of yeast colonisation and
infection was more pronounced in SDD studies compared
with SAP, whereas candidemia was reduced foremost by
SAP. SDD reduced all-cause in-hospital mortality, but both
strategies reduced yeast-related mortality. Systemic drugs
may be advised as prophylaxis in patients with a high risk of
developing Candida  bloodstream infections, whereas SDD
may be given to critically ill patients to prevent Candida colo-
nisation and infection.
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